Breast Cancer Coverage from Every Angle

Ann H. Partridge, MD, MPH: New Data on Pregnancy and Breast Cancer Treatment

Posted: Thursday, January 5, 2023

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses the importance of incorporating patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer, in light of results from the POSITIVE trial. The study showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy does not affect short-term disease outcomes. Dr. Partridge discusses the practical clinical considerations of pregnancy and cancer therapy and the plans for long-term follow-up.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.